SOURCE: OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals, Inc.

June 21, 2017 09:37 ET

OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

BATON ROUGE, LA--(Marketwired - June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that that the Mexican Institute of Industrial Property has issued patent No. 343266, titled "Composition and Method for Treating Cancer," protecting the intellectual rights of OncBioMune's ProscaVax throughout Mexico until January 8, 2032.

ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune's intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents and patents pending spanning approximately 50 countries worldwide.

"This patent is particularly important given the Mexican markets are integral to our business model. We expect to announce the official commencement of our Phase 2/3 trial of ProscaVax for late-stage prostate cancer in Mexico any day now, so the timing of the new patent couldn't be any better," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "An aging population and widespread adoption of screening for prostate specific antigen have Mexico facing a prostate cancer dilemma with little alternatives free of unpleasant side effects. We are optimistic that ProscaVax can provide a safe and effective solution to the nation's problem for years to come."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information